Kiniksa Pharmaceuticals Ltd expected to post a loss of 17 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

21/07/2023 14:19

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports  results on
July 25. 
    * The Hamilton Bermuda-based   company is expected to report
 a
93.5% increase in revenue to $52.196 million from $26.97 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Kiniksa
Pharmaceuticals
Ltd is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $21.5​, above​ its last closing price
of $15.19. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.22       -0.21      -0.18     Beat    13.3
 Dec. 31 2023  -0.23       -0.23      0.06      Beat    125.8
 Sep. 30 2022  0.79        0.78       3.18      Beat    306.4​
 Jun. 30 2022  -0.45       -0.44      -0.29     Beat    34.5
 ​​Mar.        -0.40       -0.41      -0.36     Beat    11.5
 31 2022                                                
 Dec. 31 2021  -0.42       -0.42      -0.53     Missed  -26.2​
 Sep. 30 2021  -0.65       -0.65      -0.44     Beat    32
 Jun. 30 2021  -0.94       -0.79      -0.61     Beat    23
 This summary was machine generated July 21 at 13:19 GMT.  All
figures in US dollars  unless otherwise stated